Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Cancer Discov. 2021 Oct 6;12(2):502–521. doi: 10.1158/2159-8290.CD-20-1848

Figure 2. YY1 is essential for glioblastoma stem cells both in vitro and in vivo.

Figure 2.

A, Bar plots showing YY1 and CTCF expression levels in GSC1517 with shRNA-mediated knockdown of YY1 or CTCF, respectively, as determined by qRT-PCR. Data are presented as mean + SD. B-F, Relative cell viabilities of a panel of GSCs with shRNA-mediated knockdown of YY1 or CTCF at different time points. Data are presented as mean ± SD. G-I, Tumor sphere formation efficiency and self-renewal capacity were measured by extreme in vitro limiting dilution assays (ELDA) in three GSCs. P-values were determined by likelihood ratio test. J-L, Bar plots showing the number of spheres from different GSCs after YY1 knockdown at day 7. Data are presented as mean + SD. M and N, Kaplan-Meier curves showing survival of immunocompromised mice bearing intracranial tumors from GSC1517 (M) and GSC23 (N) following transduction with indicated shRNAs. P-values were determined by log-rank test. *p < 0.05, **p < 0.01 by one-way ANOVA with Dunnett multiple comparison test; ns, not significant.